DSMB case study: Decision making when a similar clinical trial is stopped early

Controlled Clinical Trials

Volumn 24, Issue 1, 2003, Pages 85-91

  Hillman, David W ^a   Louis, Thomas A ^b  

^a MAYO CLINIC   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Clinical trial; Data and Safety Monitoring Board (DSMB); Interim monitoring

Indexed keywords

GANCICLOVIR; PLACEBO;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; NEUTROPENIA; PROFESSIONAL STANDARD; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RETINITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; CLINICAL TRIALS DATA MONITORING COMMITTEES; CYTOMEGALOVIRUS INFECTIONS; DATA INTERPRETATION, STATISTICAL; GANCICLOVIR; HUMANS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 0037307422     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(02)00274-X     Document Type: Article

References (6)

1. Spector S.A., McKinley G.F., Lalezari J.P.et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. N Engl J Med. 334:1996;1491-1497. for the Roche Cooperative Oral Ganciclovir Study Group.
2. Brosgart C.L., Louis T.A., Hillman D.W.et al. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. AIDS. 12:1998;269-277. for the Terry Beirn Community Programs for Clinical Research on AIDS.
3. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons - 2002. MMWR 2002;51:1-46.
4. Writing Group for the Women's Health Initiative Investigators Risks and benefits of estrogen plus progestin in healthy postmenopausal women. principal results from the Women's Health Initiative randomized controlled trial JAMA. 288:2002;321-333.
5. Enserink M. Epidemiology. Despite safety concerns, U.K. hormone study to proceed. Science. 297:2002;492.
6. Dixon D.O., Lagakos S.W. Should Data and Safety Monitoring Boards share confidential interim data? Control Clin Trials. 21:2000;1-6.